Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Non-Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $70.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 51.72% to $70.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.3 million, a 51.72% decrease, with the full-year FY2025 number at $70.3 million, down 51.72% from a year prior.
  • Total Non-Current Liabilities was $70.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $78.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $169.3 million in Q1 2025 to a low of $69.2 million in Q1 2023.
  • A 3-year average of $114.3 million and a median of $126.1 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: increased 11.06% in 2024, then crashed 51.72% in 2025.
  • Lexicon Pharmaceuticals' Total Non-Current Liabilities stood at $131.1 million in 2023, then rose by 11.06% to $145.5 million in 2024, then plummeted by 51.72% to $70.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Total Non-Current Liabilities are $70.3 million (Q4 2025), $78.2 million (Q3 2025), and $90.9 million (Q2 2025).